Interactions
No interaction studies were performed. However, the risk of interactions with other drugs is considered to be low.
Miscellaneous
Studies on the long-term risk and long-term benefit of Prolia® are not yet available. Also studies comparing the active ingredient Denosumab with similar drugs with a different mode of action, such as bisphosphonates, have not yet been conducted. It is currently uncertain whether the drug has an additional benefit compared to similar substances and is still under discussion.
